ArticleFrontiers in immunology2026
High-resolution mapping of chromatin conformation in HBeAg-treated macrophage provides insights into pathogenesis of HBV-related liver diseases.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) e antigen (HBeAg) plays a critical role in inducing macrophage activation and subsequent immune tolerance, which facilitates viral immune escape. However, the underlying spatial 3D genomic and epigenetic mechanisms driving this macrophage dysfunction remain largely unknown. Methods: To map the topological and transcriptional regulatory landscape, we integrated RNA-sequencing (RNA-seq), high-throughput chromosome conformation capture (Hi-C), and chromatin immunoprecipitation-sequencing (ChIP-seq) to comprehensively analyze control and HBeAg-stimulated macrophages. Key findings were cross-validated using human HBV-infected datasets. Result: HBeAg robustly activated pro-inflammatory transcriptional programs, prominently featuring the TNF signaling pathway as a central node. Hi-C analysis revealed profound global 3D chromatin reorganization accompanying this phenotypic shift. Specifically, inactive-to-active (B-to-A) compartment switching, coupled with Conclusion: HBeAg orchestrates a highly coordinated hierarchical restructuring of the 3D genome and targeted epigenetic reprogramming to induce macrophage dysfunction. The identified structural variants and core spatial-target genes (such as MET, FLNB, and BLVRB) provide novel mechanistic insights and represent potential therapeutic targets for HBV-related liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.